Search Result

Results for "

mTOR-inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	mTOR (64) Akt (1) Antibiotic (1) Apoptosis (10) Autophagy (15) Bacterial (2) Deubiquitinase (1) DNA-PK (3) Drug Metabolite (1) Endogenous Metabolite (1) FKBP (2) Fungal (1) HDAC (2) HSP (1) Isotope-Labeled Compounds (1) Mitophagy (1) PI3K (31)
By Research Areas:	Cancer (62) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: mTOR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18353

mTOR inhibitor-3 3 Publications Verification	mTOR	Cancer
mTOR inhibitor-3 is a remarkably selective *mTOR* inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

HY-131344

mTOR inhibitor-8	mTOR Autophagy	Cancer
mTOR inhibitor-8 is an *mTOR* inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .

HY-155376

mTOR inhibitor-14	mTOR	Cancer
mTOR inhibitor-14 (compound 14c) is a potent *mTOR* inhibitor. mTOR inhibitor-14 also shows minimal CYP2C8 inhibition. mTOR inhibitor-14 can inhibit tumor growth .

HY-154958

mTOR inhibitor-12	mTOR	Neurological Disease
mTOR inhibitor-12 (Compound 11) is a selective brain penetrant *mTOR* inhibitor without genotoxicity risk. mTOR inhibitor-12 can be used for the research of CNS diseases .

HY-154957

mTOR inhibitor-11	mTOR	Neurological Disease
mTOR inhibitor-11 (Compound 9) is a brain-penetrant *mTOR* inhibitor (IC₅₀: 21 nM for pS6). mTOR inhibitor-11 also inhibits pCHK1 and PDE4D with IC₅₀s of 17.2 and 17.0 μM. mTOR inhibitor-11 can be used for research of CNS disease .

HY-160548

mTOR inhibitor-18	mTOR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
mTOR inhibitor-18 (Example 106) is a *mTOR* inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders .

HY-155211

mTOR inhibitor-13	mTOR PI3K	Cancer
mTOR inhibitor-13 (compound 9g), an aryl ureido compound, is a potent and selective *mTOR* inhibitor with an IC₅₀ of 0.29 nM. mTOR inhibitor-13 also inhibits PI3K-α with an IC₅₀ of 119 nM .

HY-112914

mTOR inhibitor-1 3 Publications Verification	mTOR Autophagy	Cancer
mTOR inhibitor-1 (Compound C-4) is an ATP-Competitive *mTOR* inhibitor which can suppress cells proliferation and inducing autophagy .

HY-111370

mTOR inhibitor-2	mTOR	Cancer
mTOR inhibitor-2 is a highlt potent, selective and oral *mTOR* inhibitor with an IC₅₀ of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates .

HY-118712

mTOR inhibitor WYE-23	mTOR	Cancer
mTOR inhibitor WYE-23 is a *mTOR* inhibitor, and IC₅₀ is 0.45 nM. It is selective to PI3Kα and IC₅₀ is 661 nM. mTOR inhibitor WYE-23 has antitumor activity .

HY-118717

mTOR inhibitor WYE-28	mTOR	Cancer
mTOR inhibitor WYE-28 (compound 28) is a selective inhibitor of mTOR>/b< (IC₅₀)=0.08 nM. mTOR inhibitor WYE-28 inhibits PI3Kα with an IC50 value of 6 nM. mTOR inhibitor WYE-28 shows a metabolic time (T_1/2) in nude mouse microsomes of 13 min .

HY-114414

*HDACs/mTOR Inhibitor* 1** 1 Publications Verification	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies .

HY-152238

*PI3K/mTOR Inhibitor-12*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-12 is a potent, orally active and selective *PI3K/mTOR* inhibitor with IC₅₀ values of 0.06 nM and 3.12 nM for PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-12 has antitumor activity. PI3K/mTOR Inhibitor-12 has lower liver toxicity .

HY-146016

PI3K/mTOR Inhibitor-5

PI3K mTOR Cancer

PI3K/mTOR Inhibitor-5 (compound 19a) is a potent and dual PI3K and mTOR inhibitor, with IC₅₀ values of 86.9 nM and 14.6 nM, respectively .

*PI3K/mTOR Inhibitor-5*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-5 (compound 19a) is a potent and dual PI3K and *mTOR* inhibitor, with IC₅₀ values of 86.9 nM and 14.6 nM, respectively .

HY-128333

*PI3K/mTOR Inhibitor-4*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-147613

*PI3K/mTOR Inhibitor-6*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-6 displays better stability in artificial gastric fluids than gedatolisib. PI3K/mTOR Inhibitor-6 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-6 has the potential for the research of cancer diseases .

HY-151622

*PI3K/mTOR Inhibitor-11*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-11 is an orally active *PI3K/mTOR* inhibitor (IC₅₀: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .

HY-141476

*PI3K/mTOR Inhibitor-3*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-3 (compound 12), an imidazoline, is a potent PI3K and *mTOR* dual inhibitor. PI3K/mTOR Inhibitor-3 has anti-cancer activity .

HY-147614

*PI3K/mTOR Inhibitor-7*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-7 shows 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC₅₀ values). PI3K/mTOR Inhibitor-7 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-7 has the potential for the research of cancer diseases .

HY-156445

*PI3K/mTOR Inhibitor-14*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-14 (compound Y-2) is a potent PI3K and *mTOR* dual inhibitor with IC₅₀s of 171.4 nM and 10.1 nM, respectively. PI3K/mTOR Inhibitor-14 has antitumor activities .

HY-153120A

*PI3K/mTOR Inhibitor-13 sodium*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-153120

*PI3K/mTOR Inhibitor-13*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-146200

*PI3K/mTOR Inhibitor-8*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-8 (Compound 18b) is a PI3K and *mTOR* dual inhibitor with IC₅₀ values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-8 induces HCT-116 cells apoptosis and arrests cell cycle at the G1/S phase .

HY-112602

*PI3K/mTOR Inhibitor-1*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual *PI3K/mTOR** inhibitor* with IC₅₀s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and *mTOR*, respectively . Antitumor activity .

HY-111508

*PI3K/mTOR Inhibitor-2* 1 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR* inhibitor* with IC₅₀s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for *mTOR* . Antitumor activity .

HY-147285

*PI3K/mTOR Inhibitor-9*	mTOR PI3K	Neurological Disease
PI3K/mTOR Inhibitor-9 (Compound 1) is a potent *mTOR* and PI3K inhibitor with IC₅₀ values of 38 nM, 6.6 μM, 6.6 μM and 0.8 μM against mTOR (phospho-S6 cellular assay), PI3Kα, PI3Kγ and PI3Kδ, respectively .

HY-141805

MHY-1685

mTOR Cancer

MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.
HY-100470

NSC781406

2 Publications Verification

PI3K mTOR Cancer

NSC781406 is a highly potent PI3K and mTOR inhibitor with an IC₅₀ of 2 nM for PI3Kα.
HY-136583

28-Epirapamycin

Drug Metabolite Others

28-Epirapamycin is an impurity of Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells .
HY-50710

KU-0063794

10+ Cited Publications

mTOR Cancer

KU-0063794 is a potent and specific mTOR inhibitor, inhibiting both the mTORC1 and mTORC2 complexes with IC₅₀s of 10 nM.
HY-12763

GNE-317

1 Publications Verification

PI3K mTOR Cancer

GNE-317 is a PI3K/mTOR inhibitor, is able to cross the blood-brain barrier (BBB).

MHY-1685	mTOR	Cancer
MHY-1685, a novel mammalian target of rapamycin *(mTOR)* inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

NSC781406 2 Publications Verification	PI3K mTOR	Cancer
NSC781406 is a highly potent PI3K and *mTOR* inhibitor with an IC₅₀ of 2 nM for PI3Kα.

28-Epirapamycin	Drug Metabolite	Others
28-Epirapamycin is an impurity of Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells .

KU-0063794 10+ Cited Publications	mTOR	Cancer
KU-0063794 is a potent and specific *mTOR* inhibitor, inhibiting both the mTORC1 and mTORC2 complexes with IC₅₀s of 10 nM.

GNE-317 1 Publications Verification	PI3K mTOR	Cancer
GNE-317 is a *PI3K/mTOR** inhibitor*, is able to cross the blood-brain barrier (BBB).

HY-15247

Vistusertib 20+ Cited Publications AZD2014	mTOR Autophagy Apoptosis	Cancer
Vistusertib (AZD2014) is an ATP competitive *mTOR* inhibitor with an IC₅₀ of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.

HY-128027

eCF309

mTOR Cancer

eCF309 is a potent and highly selective mTOR inhibitor with remarkably low off-target activities (IC₅₀ = 10-15 nM, both in vitro and in cells) .

eCF309	mTOR	Cancer
eCF309 is a potent and highly selective *mTOR* inhibitor with remarkably low off-target activities (IC₅₀ = 10-15 nM, both in vitro and in cells) .

HY-13806

XL388 3 Publications Verification	mTOR Autophagy	Cancer
XL388 is a highly potent and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 9.9 nM. XL388 simultaneously inhibits both mTORC1 and mTORC2.

HY-100222

CZ415

3 Publications Verification

mTOR Cancer

CZ415 is a potent and highly selective mTOR inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

CZ415 3 Publications Verification	mTOR	Cancer
CZ415 is a potent and highly selective *mTOR* inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

HY-15248

GDC-0349 2 Publications Verification	mTOR Autophagy	Cancer
GDC-0349 is a potent and selective ATP-competitive *mTOR* inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.

HY-50908

Ridaforolimus 5+ Cited Publications MK-8669; Deforolimus; AP23573	mTOR Autophagy Bacterial	Cancer
Ridaforolimus (MK-8669) is a potent and selective *mTOR* inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC₅₀ of 0.2 nM in HT-1080 cells .

HY-12424A

42-(2-Tetrazolyl)rapamycin	Others	Cancer
42-(2-Tetrazolyl)rapamycin is a proagent compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor.

HY-10474

Torkinib 15+ Cited Publications PP 242	mTOR Autophagy Mitophagy Apoptosis	Cancer
Torkinib (PP 242) is a selective and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 8 nM . PP242 inhibits both mTORC1 and mTORC2 with IC₅₀s of 30 nM and 58 nM, respectively .

HY-136660

PQR626	mTOR	Neurological Disease
PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant *mTOR* inhibitor, with an IC₅₀ and K_i of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders .

HY-15272

WAY-600 5 Publications Verification	mTOR	Inflammation/Immunology Cancer
WAY-600 is a potent, ATP-competitive, and selective *mTOR* inhibitor with an IC₅₀ of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.

HY-118704

P-2281	mTOR	Inflammation/Immunology Cancer
P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P-2281 suppresses dextran sulfate sodium (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human colitis .

HY-10219

Rapamycin Maximum Cited Publications 728 Publications Verification Sirolimus; AY-22989	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-124036

DS-7423

PI3K mTOR Cancer

DS-7423 is a dual PI3K and mTOR inhibitor, with IC₅₀ values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity .

DS-7423	PI3K mTOR	Cancer
DS-7423 is a dual PI3K and *mTOR* inhibitor, with IC₅₀ values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity .

HY-10219GL

Rapamycin (GMP Like) Sirolimus (GMP Like); AY-22989 (GMP Like)	mTOR	Cancer
Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific *mTOR* inhibitor .

HY-13847

GNE-555	mTOR	Cancer
GNE-555 is a selective, metabolically stable *mTOR* inhibitor (K_i=1.5 nM) that also has good oral bioavailability. GNE-555 exhibits antiproliferative activity on PC3 and MCF-7 cells and can be used in cancer research .

HY-10219S

Rapamycin-d3 Sirolimus-d₃; AY-22989-d₃	mTOR FKBP Autophagy	Cancer
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

HY-154910

CC214-1	mTOR	Cancer
CC214-1 is a potentially efficacious *mTOR* inhibitor that induces autophagy ,with an IC₅₀ is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of *mTOR* kinase biology. CC214-1 can be used for Glioblastoma study .

HY-144295

PI3Kα-IN-5	PI3K mTOR	Cancer
PI3Kα-IN-5 (compound 6 ab) is a potent PI3Kα/mTOR inhibitor, with an IC₅₀ of 0.7 nM and 3.3 nM, respectively. PI3Kα-IN-5 can be used for the research of colorectal cancer .

HY-150061

NVP-BBD130	PI3K mTOR	Cancer
NVP-BBD130 is a potent, stable, ATP-competitive and orally active dual PI3K and *mTOR* inhibitor . NVP-BBD130 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10219

Rapamycin 725+ Cited Publications Sirolimus; AY-22989	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Source classification Disease Research Endogenous metabolite Disease Research Fields Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

HY-10219S1

Rapamycin-13C,d3

Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks